Medical adjustment of alcohol use disorder (AUD) with opioids

被引:0
作者
Ulmer, Albrecht [1 ]
机构
[1] Inst Addict Res, Schwabstr 26, D-70197 Stuttgart, Germany
关键词
Alcohol Use Disorder; AUD; Opioids; Dihydrocodeine; DHC; Buprenorphine; DEPENDENCE; NALTREXONE; BUPRENORPHINE; DRINKING;
D O I
10.62401/2531-4122-2024-57
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Alcohol Use Disorder (AUD) is among the most important chronic diseases in the world. In contrast to almost all other chronic diseases, there is still no long-term drug treatment and, thus, no ongoing medical care. However, in our specialised practice, we have been able to document for decades that AUD patients can be effectively treated with long-term medication. An agonistic approach has proven to be far superior to an antagonistic one. In principle, this can be done with several agonistic substances. We have achieved by far the best effects with opioids, especially with dihydrocodeine (DHC), and in smaller numbers also with buprenorphine. 24.6% of all 116 people treated with DHC for AUD achieved stable symptom-free status over the years. The University of Grenoble also reports similar experiences with buprenorphine, and similar experiences have been observed in rats in Italy. For two years, there have been first experiences with DHC at a small centre in Berlin. If we can prescribe effective drugs to treat AUD, this opens up completely new possibilities to have a decisive positive influence on the serious chronic disease through long-term care. To be able to test these experiences in international networking at other centres with guaranteed observance of special caution standards, an international network, INTAUD, was founded in June 2024. This treatment may not be carried out without observing these standards, because incorrect intake is life-threatening.
引用
收藏
页数:4
相关论文
共 21 条
  • [1] Supervised Disulfiram's Superior Effectiveness in Alcoholism Treatment: Ethical, Methodological, and Psychological Aspects
    Brewer, Colin
    Streel, Emmanuel
    Skinner, Marilyn
    [J]. ALCOHOL AND ALCOHOLISM, 2017, 52 (02): : 213 - 219
  • [2] Sodium oxybate in maintaining alcohol abstinence in alcoholic patients with and without psychiatric comorbidity
    Caputo, Fabio
    Francini, Sara
    Brambilla, Romeo
    Vigna-Taglianti, Federica
    Stoppo, Michela
    Del Re, Arfedele
    Leggio, Lorenzo
    Addolorato, Giovanni
    Zoli, Giorgio
    Bernardi, Mauro
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2011, 21 (06) : 450 - 456
  • [3] Buprenorphine reduces alcohol drinking through activation of the nociceptin/orphanin FQ-NOP receptor system
    Ciccocioppo, Roberto
    Economidou, Daina
    Rimondini, Roberto
    Sommer, Wolfgang
    Massi, Maurizio
    Heilig, Markus
    [J]. BIOLOGICAL PSYCHIATRY, 2007, 61 (01) : 4 - 12
  • [4] DEMATTEIS M., 2018, French J Psychiatry, V1, pS126, DOI [10.1016/s2590, DOI 10.1016/S2590]
  • [5] ELIAS H., 1996, SUCHTM K DGDS KONGR, P19
  • [6] FROEHLICH J. C., 1993, Opioid Peptides, DOI [10.1007/978-1-4899-1742-3_12, DOI 10.1007/978-1-4899-1742-3_12]
  • [7] GIANOULAKIS C, 1993, J PSYCHIATR NEUROSCI, V18, P148
  • [8] GRIMM G, 1992, Drugs against Drugs
  • [9] Excess Mortality of Alcohol-Dependent Individuals After 14 Years and Mortality Predictors Based on Treatment Participation and Severity of Alcohol Dependence
    John, Ulrich
    Rumpf, Hans-Juergen
    Bischof, Gallus
    Hapke, Ulfert
    Hanke, Monika
    Meyer, Christian
    [J]. ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2013, 37 (01) : 156 - 163
  • [10] Supervised Disulfiram in the Treatment of Alcohol Use Disorder: A Commentary
    Krampe, Henning
    Spies, Claudia D.
    Ehrenreich, Hannelore
    [J]. ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2011, 35 (10) : 1732 - 1736